Plasma disposition of two hydrochloride suspensions in healthy pigs
Animal study · 24 healthy Landrace pigs; 12 male and 12 female; randomized two-period, two-treatment crossover with a 7-day washout. [1]
The two suspensions produced similar plasma exposure in this crossover experiment. HPLC quantified ceftiofur and DFC-related metabolites after conversion to DFC. All animals remained healthy and no adverse reactions were observed; this single-dose observation is not a general safety assessment.
| Endpoint | Reported result | Reference |
|---|---|---|
| Plasma ceftiofur and DFC-related metabolites | Cmax Test: 34.6 ± 5.5 µg/ml; reference: 36.1 ± 6.2 µg/ml (mean ± SD, n=24). | [1] |
| Plasma ceftiofur and DFC-related metabolites | AUC0-t Test: 376.7 ± 75.3 µg·hr/ml; reference: 390.5 ± 78.6 µg·hr/ml (mean ± SD, n=24). | [1] |
| Relative exposure of test versus reference suspension | Relative bioavailability 96.47 ± 10.92% (mean ± SD, n=24). | [1] |
| Between-formulation comparison of Cmax, AUC0-t and AUC0-∞ | Statistical comparison No statistically significant differences reported. | [1] |
Conditions shared by the study groups
- Route
- Intramuscular
- Frequency
- Once per period
- Treatment course
- One dose
| Group / dose | Comparator | Observed result | Reference |
|---|---|---|---|
| Test suspension 5 mg/kg body weight | Active reference suspension in the same pigs in the other period | Cmax 34.6 ± 5.5 µg/ml; AUC0-t 376.7 ± 75.3 µg·hr/ml (mean ± SD, n=24). | [1] |
| Reference suspension 5 mg/kg body weight | Test suspension in the same pigs in the other period | Cmax 36.1 ± 6.2 µg/ml; AUC0-t 390.5 ± 78.6 µg·hr/ml (mean ± SD, n=24). | [1] |
- Test suspension
- Model: Healthy Landrace pigs in crossover
- Vehicle: Saifukang 5% CEF sterile suspension
- Reference suspension
- Model: Healthy Landrace pigs in crossover
- Vehicle: Excenel RTU 5% CEF sterile suspension
Methods and source locations
Compound reported in the paper: Ceftiofur hydrochloride; Compound label in the paper: Saifukang 5% CEF (test) and Excenel RTU 5% CEF (reference)
Disposition of the named suspensions in pigs; neither an assay IC50 nor evidence of Adooq lot performance.
Materials and Methods; Results Tables 1–4; Figure 1/caption
Plasma ceftiofur and DFC-related metabolites: HPLC following conversion to DFC; observed maximum concentrations. — Table 2; Analysis of plasma CEF and DFC-related metabolites concentrations
Plasma ceftiofur and DFC-related metabolites: Linear trapezoidal calculation. — Table 2; Pharmacokinetic and bioequivalence analysis
Relative exposure of test versus reference suspension: Based on AUC0-t; relative, not absolute, bioavailability. — Table 2; Bioequivalence analysis
Between-formulation comparison of Cmax, AUC0-t and AUC0-∞: Log-transformed parameter comparison by ANOVA. — Bioequivalence analysis; Table 3
Test suspension · Drugs and reagents; Bioequivalence study design; Table 2
Reference suspension · Drugs and reagents; Bioequivalence study design; Table 2